Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Lamb Weston Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $359.17 (market cap $9.55B), while Lamb Weston Holdings Inc trades at $53.84 (market cap $7.30B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Lamb Weston Holdings Inc pays a 2.86% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LW | |
|---|---|---|
Market Cap | $9.55B | $7.30B |
Sector | Health | Consumer Staples |
52-Week High | $362.08 | $66.57 |
52-Week Low | $241.71 | $38.48 |
Enterprise Value | $9.31B | $11.18B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Lamb Weston (LW) trades at $53.10, up 2.49% with a bullish technical signal. The stock shows strong earnings momentum with four consecutive quarterly beats, including Q2 2026 EPS of $0.87 versus $0.62 expected. Valuation metrics include a P/E of 25.28 and P/S of 1.11. Recent news highlights institutional buying and upcoming management participation in investor events, while fundamentals show $6.45B revenue with 4.39% net margin.
LW presents a mixed outlook with solid operational performance offset by margin pressure. The consensus price target of $53.86 offers limited upside, while analyst sentiment leans neutral (63% Hold). Key risks include international headwinds and cost inflation, but North American volume growth and dividend yield of 3.1% provide support. The stock trades near fair value with balanced risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
